Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Director Of 510(k) Pre-Market Notification Staff Makes Her Exit

This article was originally published in The Gray Sheet

Executive Summary

Heather Rosecrans, the long-time head of the 510(k) pre-market review section at FDA's device center, says it's time for her to move on

You may also be interested in...



Former Director Of FDA's 510(k) Staff To Join Trade Group MDMA

Heather Rosecrans, erstwhile director of FDA's 510(k) pre-market program staff, is joining the Medical Device Manufacturers Association to work on regulatory policy for the industry lobbying group

Former Director Of FDA's 510(k) Staff To Join Trade Group MDMA

Heather Rosecrans, erstwhile director of FDA's 510(k) pre-market program staff, is joining the Medical Device Manufacturers Association to work on regulatory policy for the industry lobbying group

People In Brief

FDA 510(k) director joins Greenleaf: Heather Rosecrans Sept. 28 follows former CDRH Director Dan Schultz to the consulting firm Greenleaf Health, where she will serve as a senior regulatory advisor working with Greenleaf clients to advance innovative devices (1"The Gray Sheet" Sept. 20, 2010). Other former FDAers at Greenleaf include former deputy chief of staff Taryn Fritz Warpole and former FDA Commissioner Andrew von Eschenbach. Former FDA Chief of Staff Patrick Ronan founded the Washington, D.C., and Portola Valley, Calif., firm

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT029394

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel